YASMIN Drug Patent Profile

Which patents cover Yasmin, and when can generic versions of Yasmin launch?

Yasmin is a drug marketed by Bayer Hlthcare and is included in one NDA.

The generic ingredient in YASMIN is drospirenone; ethinyl estradiol. There are eleven drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the drospirenone; ethinyl estradiol profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Yasmin

A generic version of YASMIN was approved as drospirenone; ethinyl estradiol by DR REDDYS LABS SA on September 7^th, 2010.

Summary for YASMIN

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	9
Clinical Trials:	36
Patent Applications:	241
Formulation / Manufacturing:	see details
Drug Prices:	Drug price information for YASMIN
Drug Sales Revenues:	Drug sales revenues for YASMIN
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for YASMIN
What excipients (inactive ingredients) are in YASMIN?	YASMIN excipients list
DailyMed Link:	YASMIN at DailyMed

See drug prices for YASMIN

Recent Clinical Trials for YASMIN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Women's Hospital School Of Medicine Zhejiang University	Phase 4
Inonu University	N/A
University of North Carolina, Chapel Hill	Phase 2

See all YASMIN clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for YASMIN

G03AC	Progestogens
G03A	HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE
G03	SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
G	Genito-urinary system and sex hormones

G03CA	Natural and semisynthetic estrogens, plain
G03C	ESTROGENS
G03	SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
G	Genito-urinary system and sex hormones

Paragraph IV (Patent) Challenges for YASMIN

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
YASMIN	Tablets	drospirenone; ethinyl estradiol	3 mg/0.03 mg	021098	1	2005-01-07

US Patents and Regulatory Information for YASMIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bayer Hlthcare	YASMIN	drospirenone; ethinyl estradiol	TABLET;ORAL-28	021098-001	May 11, 2001	AB	RX	Yes	Yes

Expired US Patents for YASMIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bayer Hlthcare	YASMIN	drospirenone; ethinyl estradiol	TABLET;ORAL-28	021098-001	May 11, 2001
Bayer Hlthcare	YASMIN	drospirenone; ethinyl estradiol	TABLET;ORAL-28	021098-001	May 11, 2001
Bayer Hlthcare	YASMIN	drospirenone; ethinyl estradiol	TABLET;ORAL-28	021098-001	May 11, 2001

International Patents for YASMIN

See the table below for patents covering YASMIN around the world.

Country	Patent Number	Title	Estimated Expiration
Denmark	0398460
Australia	6716700
China	1407895

Supplementary Protection Certificates for YASMIN

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1214076	49/2008	Austria		PRODUCT NAME: WIRKSTOFFKOMBINATION VON ETHINYLESTRADIOL UND DROSPIRENON; REGISTRATION NO/DATE: 1-27586 20080612
2588114	LUC00227	Luxembourg		PRODUCT NAME: DROSPIRENONE; AUTHORISATION NUMBER AND DATE: 31332 20191022
0398460	04C0022	France		PRODUCT NAME: ESTRADIOL ANHYDRE DROSPIRENONE; REGISTRATION NO/DATE IN FRANCE: NL 28661 DU 20040316; REGISTRATION NO/DATE AT EEC: RVG 27505 DU 20021211